Unknown PHASE3 INTERVENTIONAL 2-arm NCT02194634

Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)

Sponsor: Chengdu Kanghong Biotech Co., Ltd.

Interventions Conbercept Laser Sham injection Sham laser

Updated 8 times since 2017 Last updated: Jan 5, 2016 Started: Jul 31, 2014 Primary completion: Dec 31, 2016 Completion: Sep 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02194634, this PHASE3 trial focuses on Diabetic Macular Edema and remains ongoing. Sponsored by Chengdu Kanghong Biotech Co., Ltd., it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Feb 2019 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 3 earlier versions

Jun 2018 — Feb 2019 [monthly]

Unknown Status PHASE3
Oct 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE3

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chengdu Kanghong Biotech Co., Ltd.

Data source: Chengdu Kanghong Biotech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Chengdu, China , Chongqing, China , Guangzhou, China , Shanghai, China , Shenyang, China , Tianjin, China , Wenzhou, China , Wuhan, China , Wuxi, China and 2 more locations